Home › Companies › Syndax Pharmaceuticals, Inc. › 2024-2025

Syndax Pharmaceuticals, Inc. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and Syndax Pharmaceuticals, Inc.’s Form 8-K, filed May 16, 2025 (Item 5.07 on EDGAR). Page generated October 18, 2026.

5Ballot items
222Asset managers
1,045Fund votes
May 14, 2025Meeting date

Results at a glance

Meeting of May 14, 2025: 5 items on Syndax Pharmaceuticals, Inc.’s Form 8-K, filed May 16, 2025: 5 without a stated outcome.

Material dissent

Elect Director: Dennis G. Podlesak 71% of votes cast Outcome not stated Director under 80%

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Syndax Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by Syndax Pharmaceuticals, Inc.

These tallies are Syndax Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 16, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Syndax Pharmaceuticals, Inc. — official shareholder meeting results, meeting held May 14, 2025
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Keith A. Katkin	53,552,483	--	--	12,880,619	4,852,212	81%	Not verified	—
Elect Director: Dennis G. Podlesak	47,082,144	--	--	19,350,958	4,852,212	71%	Not verified	—
Elect Director: Aleksandra Rizo, M.D., Ph.D.	63,139,437	--	--	3,293,665	4,852,212	95%	Not verified	—
2. Advisory vote on executive compensation	62,495,031	3,829,672	108,399	--	4,852,212	94%	Not verified	—
3. Ratification of selection of independent registered public accounting firm	71,183,107	71,909	30,298	--	--	99.8%	Not verified	—

Source: Syndax Pharmaceuticals, Inc., Form 8-K, filed with the SEC on May 16, 2025 — read the filing on EDGAR.

How asset managers voted at the Syndax Pharmaceuticals, Inc. 2024-2025 meeting

Each item below shows how the 222 asset managers that disclosed a Syndax Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Aleksandra Rizo, M.D., Ph.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 63,139,437WITHHELD: 3,293,665

Details: description as filed, official tally, votes by 55 asset managers

Description as filed by funds: Election of Directors: Aleksandra Rizo, M.D., Ph.D.

Syndax Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Aleksandra Rizo, M.D., Ph.D.”): 63,139,437 for, 3,293,665 withheld, per its Form 8-K filed May 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 55 asset managers below reported 18,131,762 for, 427,120 withheld.

FOR

FOR: 18,131,762WITHHOLD: 427,120

Largest asset managers voting on “Election of Directors: Aleksandra Rizo, M.D., Ph.D.” at Syndax Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Withheld	Vote
Vanguard	4,649,438	0	For
BlackRock	3,921,294	0	For
Fidelity	1,965,078	0	For
State Street	1,901,899	0	For
MUTUAL FUND SERIES TRUST	1,178,062	0	For
FRANKLIN STRATEGIC SERIES	1,165,927	0	For
Charles Schwab	693,127	0	For
Dimensional	0	305,130	Withhold
Exchange Place Advisors Trust	280,520	0	For
JPMorgan	233,378	0	For
Goldman Sachs	227,788	0	For
Equitable	129,993	83,950	Mixed
TIAA	200,197	0	For
Delaware/Macquarie	180,000	0	For
QUANTITATIVE MASTER SERIES LLC	141,074	0	For
Thornburg	133,548	0	For
Jackson National	96,967	8,137	Mixed
Victory Capital	103,834	0	For
Aberdeen	99,340	0	For
Brighthouse	67,260	22,313	Mixed
Lincoln Financial	77,862	0	For
AIG/SunAmerica	71,404	0	For
John Hancock	60,983	0	For
Direxion Shares ETF Trust	55,820	0	For
ProShares	52,590	0	For

Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.

2. Elect Director: Dennis G. Podlesak

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

71% Majority: yes · of votes cast

FOR 71%WITHHELD

FOR: 47,082,144WITHHELD: 19,350,958

Details: description as filed, official tally, votes by 55 asset managers

Description as filed by funds: Election of Directors: Dennis G. Podlesak

Syndax Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Dennis G. Podlesak”): 47,082,144 for, 19,350,958 withheld, per its Form 8-K filed May 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 71% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 55 asset managers below reported 15,031,697 for, 3,527,185 withheld.

FORWITHHOLD

FOR: 15,031,697WITHHOLD: 3,527,185

Largest asset managers voting on “Election of Directors: Dennis G. Podlesak” at Syndax Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Withheld	Vote
Vanguard	4,649,438	0	For
BlackRock	3,921,294	0	For
Fidelity	1,965,078	0	For
State Street	3,288	1,898,611	Withhold
MUTUAL FUND SERIES TRUST	1,178,062	0	For
FRANKLIN STRATEGIC SERIES	1,165,927	0	For
Charles Schwab	693,127	0	For
Dimensional	0	305,130	Withhold
Exchange Place Advisors Trust	280,520	0	For
JPMorgan	233,378	0	For
Goldman Sachs	0	227,788	Withhold
Equitable	129,993	83,950	Mixed
TIAA	200,197	0	For
Delaware/Macquarie	0	180,000	Withhold
QUANTITATIVE MASTER SERIES LLC	141,074	0	For
Thornburg	133,548	0	For
Jackson National	0	105,104	Withhold
Victory Capital	0	103,834	Withhold
Aberdeen	0	99,340	Withhold
Brighthouse	32,090	57,483	Mixed
Lincoln Financial	17,056	60,806	Mixed
AIG/SunAmerica	0	71,404	Withhold
John Hancock	0	60,983	Withhold
Direxion Shares ETF Trust	0	55,820	Withhold
ProShares	0	52,590	Withhold

Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.

3. Elect Director: Keith A. Katkin

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

81% Majority: yes · of votes cast

FOR 81%WITHHELD

FOR: 53,552,483WITHHELD: 12,880,619

Details: description as filed, official tally, votes by 55 asset managers

Description as filed by funds: Election of Directors: Keith A. Katkin

Syndax Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Keith A. Katkin”): 53,552,483 for, 12,880,619 withheld, per its Form 8-K filed May 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 81% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 55 asset managers below reported 17,077,965 for, 1,480,917 withheld.

FOR

FOR: 17,077,965WITHHOLD: 1,480,917

Largest asset managers voting on “Election of Directors: Keith A. Katkin” at Syndax Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Withheld	Vote
Vanguard	4,649,438	0	For
BlackRock	3,921,294	0	For
Fidelity	1,965,078	0	For
State Street	1,900,031	1,868	For
MUTUAL FUND SERIES TRUST	1,178,062	0	For
FRANKLIN STRATEGIC SERIES	1,165,927	0	For
Charles Schwab	693,127	0	For
Dimensional	0	305,130	Withhold
Exchange Place Advisors Trust	280,520	0	For
JPMorgan	233,378	0	For
Goldman Sachs	0	227,788	Withhold
Equitable	129,993	83,950	Mixed
TIAA	200,197	0	For
Delaware/Macquarie	0	180,000	Withhold
QUANTITATIVE MASTER SERIES LLC	141,074	0	For
Thornburg	133,548	0	For
Jackson National	0	105,104	Withhold
Victory Capital	0	103,834	Withhold
Aberdeen	0	99,340	Withhold
Brighthouse	32,090	57,483	Mixed
Lincoln Financial	77,862	0	For
AIG/SunAmerica	0	71,404	Withhold
John Hancock	0	60,983	Withhold
Direxion Shares ETF Trust	0	55,820	Withhold
ProShares	0	52,590	Withhold

Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.

4. 2. Advisory vote on executive compensation

Outcome not verified Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Not verified

Combines 11 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 62,495,031AGAINST: 3,829,672

Details: description as filed, official tally, votes by 220 asset managers

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the 2025 proxy statement.

Syndax Pharmaceuticals, Inc.’s own tally for this item (“2. Advisory vote on executive compensation”): 62,495,031 for, 3,829,672 against, per its Form 8-K filed May 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 55 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at Syndax Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Against	Abstain	Vote
Vanguard	4,649,438	0	0	For
BlackRock	3,921,294	0	0	For
Fidelity	1,965,078	0	0	For
State Street	1,901,787	112	0	For
MUTUAL FUND SERIES TRUST	1,178,062	0	0	For
FRANKLIN STRATEGIC SERIES	1,165,927	0	0	For
Charles Schwab	693,127	0	0	For
Dimensional	305,130	0	0	For
Exchange Place Advisors Trust	280,520	0	0	For
JPMorgan	233,378	0	0	For
Goldman Sachs	227,788	0	0	For
Equitable	213,943	0	0	For
TIAA	200,197	0	0	For
Delaware/Macquarie	180,000	0	0	For
Simplify Exchange Traded Funds	148,217	0	0	For
QUANTITATIVE MASTER SERIES LLC	141,074	0	0	For
Thornburg	133,548	0	0	For
Jackson National	105,104	0	0	For
Victory Capital	103,834	0	0	For
Aberdeen	0	99,340	0	Against
Brighthouse	67,260	0	22,313	Mixed
Lincoln Financial	77,862	0	0	For
AIG/SunAmerica	71,404	0	0	For
John Hancock	60,983	0	0	For
Direxion Shares ETF Trust	55,820	0	0	For

Fund voting reports, all 55 managers: 18,561,659 for, 118,257 against, 22,313 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 181 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at Syndax Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Against	Vote
Kynam Capital Management, LP	7,541,277	0	For
Eversept Partners, LP	4,212,270	0	For
State Street	3,539,681	26,696	For
BlackRock	3,398,945	0	For
GEODE CAPITAL MANAGEMENT, LLC	2,024,784	0	For
FRANKLIN ADVISERS INC	2,010,667	0	For
Sofinnova Investments, Inc.	1,993,799	0	For
Woodline Partners LP	1,890,540	0	For
KINGDON CAPITAL MANAGEMENT, L.L.C.	1,804,360	0	For
Catalio Capital Management, LP	1,537,587	0	For
Point72	1,249,353	0	For
BNP Paribas Asset Management Holding S.A.	0	1,221,269	Against
Aisling Capital Management LP	1,025,000	0	For
Ensign Peak Advisors, Inc	955,237	0	For
PFM Health Sciences, LP	926,424	0	For
Avidity Partners Management LP	925,000	0	For
SILVERARC CAPITAL MANAGEMENT, LLC	755,304	0	For
Octagon Capital Advisors LP	751,819	0	For
Two Sigma	749,754	0	For
Charles Schwab	693,666	0	For
Northern Trust	647,435	4,549	For
Saturn V Capital Management LP	581,300	0	For
DAFNA Capital Management LLC	542,002	0	For
Nantahala Capital Management, LLC	524,497	0	For
Exome Asset Management LLC	486,647	0	For

Institutional-manager reports, all 181 managers: 47,496,264 for, 2,106,479 against, 1,654 abstained, 292 not voted. Showing the 25 largest; see all in the interactive database.

5. 3. Ratification of selection of independent registered public accounting firm

Outcome not verifiedAUDIT-RELATEDReported outcome: Not verified

99.8% Majority: yes · of votes cast

FOR 99.8%

FOR: 71,183,107AGAINST: 71,909

Details: description as filed, official tally, votes by 53 asset managers

Description as filed by funds: TO RATIFY THE SELECTION OF DELOITTE & TOUCHE LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

Syndax Pharmaceuticals, Inc.’s own tally for this item (“3. Ratification of selection of independent registered public accounting firm”): 71,183,107 for, 71,909 against, per its Form 8-K filed May 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of Syndax Pharmaceuticals, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Ratify Appointment of Independent Auditors” (2 managers, 148,217 for, 19,775 withheld).

The 53 asset managers below reported 18,528,101 for, 1,461 against, 22,313 abstained.

FOR

FOR: 18,528,101AGAINST: 1,461ABSTAIN: 22,313

Largest asset managers voting on “TO RATIFY THE SELECTION OF DELOITTE & TOUCHE LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIR” at Syndax Pharmaceuticals, Inc., 2024-2025
Asset manager	For	Against	Abstain	Vote
Vanguard	4,649,438	0	0	For
BlackRock	3,921,294	0	0	For
Fidelity	1,965,078	0	0	For
State Street	1,901,787	112	0	For
MUTUAL FUND SERIES TRUST	1,178,062	0	0	For
FRANKLIN STRATEGIC SERIES	1,165,927	0	0	For
Charles Schwab	693,127	0	0	For
Dimensional	305,130	0	0	For
Exchange Place Advisors Trust	280,520	0	0	For
JPMorgan	233,378	0	0	For
Goldman Sachs	227,788	0	0	For
Equitable	213,943	0	0	For
TIAA	200,197	0	0	For
Delaware/Macquarie	180,000	0	0	For
QUANTITATIVE MASTER SERIES LLC	141,074	0	0	For
Thornburg	133,548	0	0	For
Jackson National	105,104	0	0	For
Victory Capital	103,834	0	0	For
Aberdeen	99,340	0	0	For
Brighthouse	67,260	0	22,313	Mixed
Lincoln Financial	77,862	0	0	For
AIG/SunAmerica	71,404	0	0	For
John Hancock	60,983	0	0	For
Direxion Shares ETF Trust	55,820	0	0	For
ProShares	52,590	0	0	For

Showing the 25 largest of 53 asset managers. See all 53 in the interactive database.

Largest Syndax Pharmaceuticals, Inc. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 86,047,032 shares outstanding at the time of that meeting.

Fund voting reports: top Syndax Pharmaceuticals, Inc. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's named executive officers…”, 2024-2025
#	Asset manager	% of shares outstanding
1	Vanguard	5.40%
2	BlackRock	4.56%
3	Fidelity	2.28%
4	State Street	2.21%
5	MUTUAL FUND SERIES TRUST	1.37%
6	FRANKLIN STRATEGIC SERIES	1.35%
7	Charles Schwab	0.81%
8	Dimensional	0.35%
9	Exchange Place Advisors Trust	0.33%
10	JPMorgan	0.27%

Institutional-manager reports: top Syndax Pharmaceuticals, Inc. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's named executive officers…”, 2024-2025
#	Asset manager	% of shares outstanding
1	Kynam Capital Management, LP	8.76%
2	Eversept Partners, LP	4.90%
3	State Street	4.14%
4	BlackRock	3.95%
5	GEODE CAPITAL MANAGEMENT, LLC	2.35%
6	FRANKLIN ADVISERS INC	2.34%
7	Sofinnova Investments, Inc.	2.32%
8	Woodline Partners LP	2.20%
9	KINGDON CAPITAL MANAGEMENT, L.L.C.	2.10%
10	Catalio Capital Management, LP	1.79%

Reported Syndax Pharmaceuticals, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

Syndax Pharmaceuticals, Inc. holdings and ownership disclosed for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
Entities affiliated with BlackRock, Inc.	10.21%	DEF14A
BlackRock	9.93%	13F
Entities affiliated with Kynam Capital Management, LP	9.90%	DEF14A
Kynam Capital Management, LP	9.90%	13G
Vanguard Group	5.66%	13F
Point72	4.89%	13F
State Street	4.62%	13F
Goldman Sachs	4.56%	13F
Citadel Advisors	3.51%	13F
Morgan Stanley	2.65%	13F

Percentages above are of 86,047,032 shares outstanding, as reported by Syndax Pharmaceuticals, Inc. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Syndax Pharmaceuticals, Inc.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.

At Syndax Pharmaceuticals, Inc.'s shareholder meeting held May 14, 2025, in the 2024-2025 proxy season, 222 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 1,045 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — FOR was 94% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Syndax Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 16, 2025.

Syndax Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Download data (CSV): ballot items · votes by manager · column guide.